<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>School of Health Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E67A5CF-5B8A-45C0-BCF3-9176C174FDFB"><gtr:id>1E67A5CF-5B8A-45C0-BCF3-9176C174FDFB</gtr:id><gtr:name>GlaxoSmithKline PLC</gtr:name><gtr:address><gtr:line1>980 Great West Road</gtr:line1><gtr:postCode>TW8 9GS</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/15FC330D-7511-49F4-9418-C3294EA42873"><gtr:id>15FC330D-7511-49F4-9418-C3294EA42873</gtr:id><gtr:name>2-DTech Limited</gtr:name><gtr:address><gtr:line1>Core Technology Facility</gtr:line1><gtr:line2>46 Grafton Street</gtr:line2><gtr:postCode>M13 9NT</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/645ADF06-01C7-45C1-A485-7102A948B2E5"><gtr:id>645ADF06-01C7-45C1-A485-7102A948B2E5</gtr:id><gtr:name>Smith and Nephew</gtr:name><gtr:address><gtr:line1>York Science Park</gtr:line1><gtr:line2>Heslington</gtr:line2><gtr:line4>York</gtr:line4><gtr:postCode>YO10 5DF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77EDD907-E82C-4445-96DE-414526C3B18A"><gtr:id>77EDD907-E82C-4445-96DE-414526C3B18A</gtr:id><gtr:name>Graphenea S.A.</gtr:name><gtr:address><gtr:line1>Avenida de Tolosa, 76</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Spain</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84EC36D9-AAC8-496A-B69B-F9DE2213B154"><gtr:id>84EC36D9-AAC8-496A-B69B-F9DE2213B154</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DEE569E1-D0BB-4623-AEE0-54011EEFDAC9"><gtr:id>DEE569E1-D0BB-4623-AEE0-54011EEFDAC9</gtr:id><gtr:name>Janssen Pharmaceutical Companies</gtr:name><gtr:address><gtr:line1>1400 McKean &amp; Welsh Roads</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/651317F1-3E14-41E4-B11C-0E55F1243FE5"><gtr:id>651317F1-3E14-41E4-B11C-0E55F1243FE5</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Angus</gtr:otherNames><gtr:surname>Dryfe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/42128CD3-748A-4599-A4FA-AEF2F31A5835"><gtr:id>42128CD3-748A-4599-A4FA-AEF2F31A5835</gtr:id><gtr:firstName>Konstantin</gtr:firstName><gtr:surname>Novoselov</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2EFFCC2A-AA46-452B-8B71-BD23A4FC0397"><gtr:id>2EFFCC2A-AA46-452B-8B71-BD23A4FC0397</gtr:id><gtr:firstName>Irina</gtr:firstName><gtr:surname>Grigorieva</gtr:surname><gtr:orcidId>0000-0001-5991-7778</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3DBB8135-8CDE-4AE2-B6D7-0F1D96DEE547"><gtr:id>3DBB8135-8CDE-4AE2-B6D7-0F1D96DEE547</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>MacDonald</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D88789AD-FE15-4657-AB0A-275B816BB651"><gtr:id>D88789AD-FE15-4657-AB0A-275B816BB651</gtr:id><gtr:firstName>RAHUL</gtr:firstName><gtr:surname>RAVEENDRAN NAIR</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6605B94E-6B69-43F8-BB8D-A8751DFA7D44"><gtr:id>6605B94E-6B69-43F8-BB8D-A8751DFA7D44</gtr:id><gtr:firstName>Cinzia</gtr:firstName><gtr:surname>Casiraghi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2D97843F-E4A8-469D-A39A-88CA317DC3EB"><gtr:id>2D97843F-E4A8-469D-A39A-88CA317DC3EB</gtr:id><gtr:firstName>Kostas</gtr:firstName><gtr:surname>Kostarelos</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/41DC1B21-82FC-4321-A533-367233B0F611"><gtr:id>41DC1B21-82FC-4321-A533-367233B0F611</gtr:id><gtr:firstName>Igor</gtr:firstName><gtr:surname>Larrosa</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6428AFF5-B5E3-4531-8441-85698822C044"><gtr:id>6428AFF5-B5E3-4531-8441-85698822C044</gtr:id><gtr:firstName>Nicola</gtr:firstName><gtr:surname>Tirelli</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FP00119X%2F1"><gtr:id>5088A326-559E-427E-9245-30337FDCE321</gtr:id><gtr:title>2D Materials for Next Generation Healthcare Technologies (2D-Health)</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/P00119X/1</gtr:grantReference><gtr:abstractText>This Programme Grant capitalise on the world-leading expertise and research infrastructure on graphene and 2D materials available at the University of Manchester (UoM) to develop future therapies and generate innovative healthcare technology platforms by ascertaining UK leadership in biotech and pharmaceutical development.

There is an increasing need to develop new innovative technologies for healthcare, digital services and other innovation with the vision to deliver health services in more efficient ways and with benefits to patients and taxpayers. The National Health Services (NHS) is under increasing financial pressure in recent years, mainly due to population growth and an increased demand on NHS services. In addition to that, a growing ageing population associated with increased prevalence of pathologies such as cardiovascular disease, dementias, cancer and diabetes significantly add to the cost of care in the NHS. Innovative solutions for development of future therapies that could respond to such unmet clinical needs, reduce the cost burden on the NHS and provide a more effective, safer and patient-centred care is highly needed now. 

2D materials are one atom thick materials. The family of these flat crystals is very large and includes transition metal dichalcogenides, hexagonal boron nitride, and graphene among many others. Altogether, they cover a large range of properties (from conductive to insulating, from transparent to opaque, from mechanically stiff to compliant) that can be exploited for the creation of new devices and technologies with a wide range of applications. Various innovative G2D based materials and technologies have been pioneered at the University of Manchester such as the super-hydrophilic graphene oxide based membranes, 2D material water based inks for printable electronics, and graphene based printed technology for wireless wearable communication applications. These newly developed materials and technologies have great potential for use in biomedicine can be exploited for the design and engineering of novel healthcare technologies towards solutions or improvements of unmet clinical needs.

In the 2D-Health research programme, we formed a team of internationally renowned and highly esteemed multi-disciplinary researchers and some of the world-leaders in G2D research in order to utilise selected unique properties offered by G2D materials and technologies and to develop innovative solutions for specific unmet clinical needs in wound care and management (relevant to diabetes); tissue rehabilitation by electrical stimulation (relevant to dementia); cell therapeutics (relevant to cardiovascular disease); and immunotherapeutics (relevant to cancer).

This programme directly aligns to the EPSRC Healthcare Technologies priorities by aiming to develop future therapies in specific applications of unmet clinical need and draws on several cross-cutting capabilities: a) custom-design G2D materials into advanced materials under specifications aimed at a precise industry-driven use, exploring different chemical modification strategies; b) development of novel imaging and sensing technologies for tracking and monitoring therapeutic intervention; and c) develop G2D-based technologies through the preclinical stage for each of the application areas using relevant cellular and animal models. Strong partnership with industrial partners for rapid clinical translation and in collaboration with ethicists and regulators aims to ensure responsible and societally-acceptable innovations.</gtr:abstractText><gtr:potentialImpactText>Based on the ambitious objectives aimed at within the 2D-Health Programme and the broad interest in efforts to exploit 2D materials in socially-needed application areas (such as healthcare) we will generate a significant impact at the levels of scientific knowledge, end-user (industrial and clinical) engagement and the broader society. Moreover, we included public and end-user engagement as an integrated part of the programme deliverables (WorkPackage 5) that is dedicated to engagement and communication to maximise impact from the outcomes of 2D-Health programme. 

Public engagement: Developing new biomedical technologies and new therapies from emerging materials, such as 2D nanomaterials, is expected to attract significant attention from the wider public, particularly patient groups who may benefit from the successful outcomes of the Programme. The PI, Co-Is and members of their team are actively involved with various national and international public engagement outlets to describe and showcase some of the most intriguing uses of nanomaterials in medicine.

End-user engagement: We are planning on communicating the knowledge and expertise generated in this research programme to the industrial and clinical partners and through them to their wider communities. The role and contribution of the four Industrial Champions in 2D-Heath will spearhead end-user involvement and maximise the potential to develop clinically translatable technologies. They will subsequently transfer and translate the technology further for commercialisation and up-scaling. We expect that translation of such innovative technology will contribute to UK job creation, economic growth and leadership in the UK Pharma and Biotech industrial landscape. 

Ethics: The PI has a long track-record of preclinical work using in vivo models of disease. All experimental procedures will be authorised by the UK Home office and approved by University of Manchester Ethical Review Committee. The establishment of an Ethics &amp;amp; Regulatory Board chaired by Prof Bensaude-Vincent (Sorbonne) a member of the CNRS (French National Centre for Scientific Research) Ethics Committee will guarantee integration of ethical issues within the Management structure of 2D-Health, so that all ethical matters raised during the course of the Programme to be timely addressed. 

Regulation and Responsible innovation: Development of novel biomedical technologies and new therapies based on advanced materials is of great interest for regulators who want to ensure that the science and technology generated is in the public interest and is not detrimental to the environment and public health. Experts from the Medicines and Healthcare products Regulatory Agency (MHRA), Food and Drug Administration (FDA) and European Medicines Agency (EMA) will be invited to participate within the Management structures and Advisory Bodies of 2D-Health at a very early stage of the programme to secure incorporation of their advice in the vision/direction of the Programme. 

Research project design: It is expected that the size of the market for products incorporating engineered nanomaterials, including 2D materials, will grow exponentially as more industrial applications adopt them. On the forefront of such developments and within that supply chain will be some of our SME commercial partners (Graphenea, 2DTech) that up-scale processes for 2D material production. These industries will also be beneficiaries of the outcomes of this programme that will allow them to de-risk their business by know-how in production of 2D materials at biological and/or clinical grade.</gtr:potentialImpactText><gtr:fund><gtr:end>2021-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2016-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5327896</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>389AD1DD-6433-4A15-A058-7A7CDDA1DFE1</gtr:id><gtr:title>Graphene Oxide Dielectric Permittivity at GHz and Its Applications for Wireless Humidity Sensing.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22da6316775f98cb557e88c2def5104f"><gtr:id>22da6316775f98cb557e88c2def5104f</gtr:id><gtr:otherNames>Huang X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa69333aec492.53663692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00949E3D-7FE8-433D-B10A-5E3F92DD2186</gtr:id><gtr:title>Water-based and biocompatible 2D crystal inks for all-inkjet-printed heterostructures.</gtr:title><gtr:parentPublicationTitle>Nature nanotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38267566e5fbb0747eecc50aa349505c"><gtr:id>38267566e5fbb0747eecc50aa349505c</gtr:id><gtr:otherNames>McManus D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1748-3387</gtr:issn><gtr:outcomeId>5aa69383d20156.65884928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6FBAB2D-D18D-4CD9-8CF4-7193B018ACE1</gtr:id><gtr:title>Tunable sieving of ions using graphene oxide membranes.</gtr:title><gtr:parentPublicationTitle>Nature nanotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/786e75635ba89b4a3784b3a67ab84e88"><gtr:id>786e75635ba89b4a3784b3a67ab84e88</gtr:id><gtr:otherNames>Abraham J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1748-3387</gtr:issn><gtr:outcomeId>5aa693adf32904.35624431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8060337B-8163-41AE-B227-002100675A24</gtr:id><gtr:title>Translating graphene and 2D materials into medicine</gtr:title><gtr:parentPublicationTitle>Nature Reviews Materials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa2da61ae53cf5e028abeba8572405ae"><gtr:id>aa2da61ae53cf5e028abeba8572405ae</gtr:id><gtr:otherNames>Kostarelos K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5aa693cfb62377.93136871</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/P00119X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>E847DD9B-2053-4BC7-97A9-4213B185C968</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>Materials sciences</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>BD108981-2A72-4C45-AAC2-425461EB90BE</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Biomaterials</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>561091A1-9FC9-4508-B1B2-2F3623E1FC9D</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Materials Characterisation</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>063026C5-CD0B-48AB-82F3-6359499A95D4</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Materials Synthesis &amp; Growth</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>16595C3C-600D-4AD2-B394-16E06F96495F</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Med.Instrument.Device&amp; Equip.</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>